About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Shareholder Information Analyst Coverage Corporate Governance AIM Rule 26 Advisers General Meeting Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 20 Sep 2018 Financial Results for Second Quarter Ended 31 July 2018 Press Releases / 14 Sep 2018 Summit Therapeutics to Participate in Upcoming Investor Conferences Press Releases / 14 Sep 2018 Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Press Releases / 06 Sep 2018 Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Press Releases / 05 Sep 2018 Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea Press Releases / 16 Aug 2018 Summit Awarded Additional $12 Million by BARDA for Ridinilazole Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Press Releases / 27 Jun 2018 Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Press Releases / 11 Jun 2018 Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018 Press Releases / 07 Jun 2018 Result of AGM Press Releases / 05 Jun 2018 Financial Results for First Quarter Ended 30 April 2018 << 1 2 3 … 23 24 >>
Press Releases / 20 Sep 2018 Financial Results for Second Quarter Ended 31 July 2018 Press Releases / 14 Sep 2018 Summit Therapeutics to Participate in Upcoming Investor Conferences Press Releases / 14 Sep 2018 Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Press Releases / 06 Sep 2018 Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Press Releases / 05 Sep 2018 Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea Press Releases / 16 Aug 2018 Summit Awarded Additional $12 Million by BARDA for Ridinilazole Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Press Releases / 27 Jun 2018 Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Press Releases / 11 Jun 2018 Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018 Press Releases / 07 Jun 2018 Result of AGM Press Releases / 05 Jun 2018 Financial Results for First Quarter Ended 30 April 2018
Press Releases / 14 Sep 2018 Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
Press Releases / 06 Sep 2018 Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
Press Releases / 05 Sep 2018 Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
